he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
拍照信源地址
下一页:隐源性高血压死亡率翻倍
- 2022-04-202013年国际抗癫痫协会抗癫痫药使用指南
- 喝奶茶容易导致男性不育。
- 第二届微创、超声介入学科发展及临床应用研讨会
- 治疗女性不孕需要多少钱?
- 每个女人都是江湖……
- 癫痫猝死:凶手是谁?
- 抗癫痫药物预防新发癫痫:任重而道远
- BMJ:血浆置换对ANCA相关性血管炎患者的影响
- 溢液的原因是什么?有些是按出来的!排毒吗?警惕血性溢液!
- 儿童癫痫的早期症状 癫痫的原因
- 研究发现,置入支架接近手术打开动脉的再堵塞风险
- 如何预防炎症 滥用抗生素小心得这种病
- Nat Biotech:人工合成酶可能为线粒体功能异常疾病提供新的疗法
- 滴虫性炎用什么药
- 害羞┃做女孩太难了!乳晕是粉色的好女孩?
- 你在中国当医生的五少痛点?
- 医生快帮我!下面有虫子!?!?”
- 治疗脑炎后遗症的方法有哪些?
- 屁股真的越翘越好吗?不良姿势造成危害,骨盆前倾需要纠正
- J Urol:在性腺功能减退患者中,肌内注射丙酸睾酮和皮射庚酸睾酮哪种效果好?
- 携手精华医院,趣孕APP用大数据助推辅助生殖“精准医疗”
- 福州一医院用嫩模照片宣传妇科被判赔偿3.2 万
- 90%的人误解这些妇科常识!
- 女人有这些特点,恭喜你,不容易得糖尿病
- 第一次同房失败,怎么治疗?
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 控制癫痫患者再次抽搐,不包括可选药物?
- 武汉率先探索异地就医门诊费用直接结算
- 病良性癫痫病有什么症状
- 最佳癫痫病治疗方法腹泻是什么
- 应用于抗癫痫药物的患者,能用抗病吗?
- 20130712养生:杨红宣讲癫痫病人不能吃掉什么
- 症状性癫痫疗法费用要多少钱
- 癫痫病的早期患者 有这些患者小心癫痫病
- 小学生开课发呆喊不醒 检查才知得了癫痫病
- 河南:无偿献血者用血费用“电子商务”减免
- 怎么放射治疗癫痫病
- 怎样治疗癫痫病治疗新方法
- 癫痫VIMPAT®3期药理学结果阳性
- 【服药问答】特发性癫痫大发作药物治疗首选?
- 羊癫疯发作的副作用体征